Clinical effect of panaxadiol saponin on non-small cell lung cancer patients with chemotherapy-induced leukopenia / 中国基层医药

ABSTRACT

Objective To explore the clinical efficacy and safety of panaxadiol saponins for the treatment of non-small cell lung cancer(NSCLC) with chemotherapy-induced leukopenia.Methods 92 NSCLC patients with leukopenia after chemotherapy were selected and divided into the observation group (46 cases) and the control group (46 cases) by random number table method.On the second day after the chemotherapy,the observation group was given panaxadiol saponins capsules,3 tablets/time,2 times/day.The control group was orally given placebo or reserpine,4 weeks for one course of treatment,the two groups were continuously treated for two courses.The clinical efficacy,number of leukocytes,improvement of TCM symptoms and adverse reactions were evaluated.Results After treatment for 4 weeks and 8 weeks,the WBC counts of the observation group were (4.48 ±0.77) × 109/L and (4.92 ± 0.89) × 109/L,respectively,which were significantly higher than those of the control group[(4.02 ± O.93) × 109/L and (4.57 ± 0.86) × 109/L],the differences were statistically significant(t =8.24,8.41,all P ＜ 0.05).After treatment for 4 weeks and 8 weeks,the TCM syndrome scores of the observation group were (24.02 ± 5.91)points and (21.73 ± 4.14) points,respectively,which were lower than those of the control group [(26.33 ± 5.08) points and (23.14 ± 3.90) points],the differences were statistically significant (t =9.68,9.63,all P ＜ 0.05).After treatment for 4 weeks and 8 weeks,the total effective rates of TCM were 76.09％ (35/46) and 82.61％ (38/46),respectively,which were significantly higher than those of the control group [63.04％ (29/46) and 63.04％ (29/46)],the differences were statistically significant(x2 =10.32,8.61,all P ＜ 0.05).The effective rates of leukopenia improvement of the observation group after treatment for 4 weeks and 8 weeks were 69.57％ (32/46) and 78.26％ (36/46),respectively,which were higher than those of the control group [56.52％ (26/46) and 65.22％ (30/46)],the differences were statistically significant(t =9.38,9.51,all P ＜ 0.05).There were no significant differences in adverse reactions between the two groups (P ＞ 0.05).Conclusion Panaxadiol saponins in the treatment of NSCLC chemotherapy-induced leukopenia can significantly improve the number of white blood cells,improve the clinical symptoms,and it has good safety.